Clinical Trials on Bladder Tumor (TURBT) in Portugal

Total 120 results

Hospital Beatriz Ângelo
Bristol-Myers Squibb; Universidade Nova de Lisboa; Instituto de Patologia e Imunologia...

Withdrawn

Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

Germ Cell Tumors

Portugal
Pfizer

Completed

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Urinary Bladder, Overactive

Portugal
Vensica Therapeutics Ltd.

Completed

Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

Overactive Bladder

Czechia, Portugal
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Vensica Therapeutics Ltd.
Blueclinical, Ltd.

Completed

Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects (XAVIER)

Overactive Bladder

Portugal
University of Oxford
King's College London; Bayer; Boston Children's Hospital; Queen Mary University... and other collaborators

Completed

Translational Research in Pelvic Pain (TRiPP)

Chronic Pain | Endometriosis | Bladder Pain Syndrome

United Kingdom, Portugal
Sanofi

Completed

SSR240600C Treatment in Women With Overactive Bladder (BILADY)

Overactive Bladder

France, Germany, Netherlands, Portugal, Czech Republic, United States, Canada
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
European Organisation for Research and Treatment...

Completed

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, United Kingdom, Italy, Portugal, Turkey
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Portugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
Hospital de Santa Maria, Portugal
Centro Hospitalar Lisboa Norte; Instituto de Medicina Molecular João Lobo Antunes

Completed

Circulating Tumor Cell Reducing No-touch Nephrectomy (CITO-CERENE)

Renal Cell Carcinoma | Circulating Tumor Cell

Portugal
Novartis Pharmaceuticals

Completed

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Malignant Melanoma

Portugal
Sanofi

Completed

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction (ALFACHIN)

Neurogenic Urinary Bladder

United States, France, Canada, Poland, Germany, Portugal, Spain, Turkey, Bulgaria, Estonia, India, Malaysia, Philippines, Russian Federation, Serbia, Singapore, Slovakia, Taiwan
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Centro Hospitalar de Lisboa Central
Ophiomics - Precision Medicine

Recruiting

HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma (HepatoPredict)

Recurrence Tumor | Hepatocellular Carcinoma, Scirrhous

Portugal
European Organisation for Research and Treatment...

Completed

Surgery and BCG in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, France, Austria, United Kingdom, Israel, Italy, Turkey, Greece, Portugal, Romania
Bayer

Completed

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) (OVADER)

Overactive Bladder

Austria, Singapore, New Zealand, Australia, Portugal, Czechia, Poland, Germany, Sweden
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
Allergan

Completed

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Overactive Bladder

Poland, United Kingdom, Portugal, South Africa, Ukraine, Australia, Netherlands, Canada, Singapore, Russian Federation, Germany, Brazil, Austria, Slovakia, Czechia, United States, Taiwan, Italy, France, Belgium, Spain, New Zealand
Hospices Civils de Lyon

Recruiting

QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management

Solid Tumor | Hematologic Cancer

Netherlands, France, Portugal, Spain
Universidade do Porto
Instituto Portugues de Oncologia, Francisco Gentil, Porto; Unidade de Saúde... and other collaborators

Recruiting

HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme (HERSELF)

Papillomavirus Infections | Cervix Cancer | Early Detection of Cancer | Self-Examination

Portugal
Bayer

Completed

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Overactive Bladder | Detrusor Overactivity

Spain, Belgium, Canada, Netherlands, Switzerland, Russian Federation, Germany, Israel, Hungary, Portugal, France, Poland, Czech Republic
Société d'Imagerie de la Femme

Unknown

EURAD-MR Classification : European Multicenter Study (EURAD)

Ovarian Tumor

United Kingdom, France, Portugal, Austria, Croatia, Italy, Serbia, Switzerland
Astellas Pharma Europe B.V.

Completed

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (AMARANTH)

Pain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder Disease

Belgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Ipsen

Terminated

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)

Pancreatic Neuroendocrine Tumor

Spain, Portugal
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

United States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Astellas Pharma Inc

Completed

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (SUNRISE)

Urinary Bladder, Overactive

France, United Kingdom, Belgium, Germany, Spain, Portugal, Greece, Russian Federation, Czech Republic, Poland, Hungary, Italy, Slovakia, Egypt
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Newly Diagnosed and Recurrent Glioblastoma

Spain, Israel, Portugal
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
European Infant Neuroblastoma Study Group - 1999

Completed

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Neuroblastoma

Switzerland, Denmark, Spain, Belgium, France, Austria, Italy, Norway, Portugal, Sweden, United Kingdom
European Infant Neuroblastoma Study Group - 1999

Completed

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma

Neuroblastoma

Switzerland, Denmark, Spain, Belgium, France, Austria, Italy, Norway, Portugal, Sweden, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
European Infant Neuroblastoma Study Group - 1999

Completed

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.

Neuroblastoma

Switzerland, Denmark, Spain, Belgium, France, Austria, Italy, Norway, Portugal, Sweden, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Netherlands, Portugal, Australia, Russian Federation, Ukraine
Societe Internationale d'Oncologie Pediatrique
Children's Cancer and Leukaemia Group

Completed

Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma

Neuroblastoma

Switzerland, Spain, Germany, Belgium, France, Denmark, Austria, Italy, Norway, Portugal, Sweden, United Kingdom
European Organisation for Research and Treatment...

Completed

Radiation Therapy in Treating Patients With Brain Cancer

Brain and Central Nervous System Tumors

Switzerland, United Kingdom, Belgium, Netherlands, Portugal, Austria, Germany, Italy
European Infant Neuroblastoma Study Group - 1999

Completed

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma

Neuroblastoma

Switzerland, Denmark, Spain, United Kingdom, Belgium, France, Austria, Italy, Norway, Portugal, Sweden
Universitätsklinikum Hamburg-Eppendorf
Deutsche Kinderkrebsstiftung

Active, not recruiting

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Brain Tumors

Germany, Denmark, United Kingdom, Belgium, Poland, Ireland, Austria, Italy, Czechia, France, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland
Advanced Accelerator Applications

Active, not recruiting

Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS)

Neuroendocrine Tumors

United Kingdom, Portugal, Spain, France, United States
Pfizer

Terminated

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Neuroblastoma

Australia, Korea, Republic of, United States, Portugal, New Zealand, Sweden
European Organisation for Research and Treatment...

Completed

Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer

Testicular Germ Cell Tumor | Ovarian Cancer | Extragonadal Germ Cell Tumor

France, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Portugal, Greece, Austria
European Organisation for Research and Treatment...

Completed

E7070 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

France, Switzerland, Norway, Belgium, United Kingdom, Germany, Austria, Portugal, Italy
University Ghent
Universidade Nova de Lisboa; Horizon 2020 - European Commission; Hospital de... and other collaborators

Recruiting

ELEVATE Acceptability Study (ELEVATE AS)

Cervical Cancer | HPV Infection | Acceptability of Health Care

Belgium, Brazil, Ecuador, Portugal
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom

Clinical Trials on Bladder Tumor (TURBT) in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations